Reviewer ’s report  
 
Title: Non-steroidal anti -inflammatory drug -induced enteropathy a s a major risk factor for small 
bowel bleeding: A retrospective study  
 
Version: 1 Date: 21 Apr 2020  
 
Reviewer: Arnaud - Alvès  
 
Reviewer's report:  
 
Please include all comments for the authors in this box rather than uploading your report as an 
attachment. Please only upload as attachments annotated versions of manuscripts, graphs, 
supporting materials or other aspects of your report which cannot be included in a text format.  
Please overwrite this teThe present ma nuscript aimed to assess the frequency of NSAIDs in 
small bowel lesions in Korean patients with obscure GI bleeding who underwent capsule 
endoscopy. This paper is well written and structured. However, there are some comments to 
make in this regard:  
 
1. A recent systematic review and meta -analysis suggested that the optical timing of 
capsule endoscopy would be within 2 days to improve diagnostic yield. Among 
patients with a claer bloody stool, how long did it take to complete the capsule 
endoscopy?  
 
Rebleedin g occurred in 7 patients during the 12 -months follow -up period.  
 
2. Of these seven patients, two had Crohn's disease. What specific treatment did they 
receive for recurrent bleeding?  
 
3. Two patients with radiation enteritis suffered from rebleeding. Surpri singly, they've 
been offered surgical treatment. It's not, however, a classic operative indication for 
radiation enteritis. Did they also have small bowel stenosis on imaging?  
 
4. Finally, multiple strictures of the small bowel were observed on CT -scan in the last 
patient. Were these strictures present prior to the recurrence of bleeding?  
 
The authors suggested the meaningful association between NSAID use and SB injury.  
 
5. Did the authors recommend the use of capsule endoscopy in case of obscure GI 
bleedin g? If that's the case, how soon can this endoscopic capsule be completed?  
 
xt when adding your comments to the authors.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments t o the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Unable to assess  
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain i n your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manus cript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please speci fy what aspects require further 
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing inter ests, considering the following questions:  
 
1.  Have you in the past five years received reimbursements, f ees, funding, or salary 
from an organisation that may in any way gain or lose financial ly from the 
publication of this manuscript, either now or in the future?  
 
2.  Do you hold any stocks or shares in an organisation t hat may in any way gain or 
lose financially from the publication of this manuscript, either now or in the 
future?  
 
3.  Do you hold or are you currently applying for any patents relating to the c ontent 
of the manuscript?  
 
4.  Have you received reimbursements, fees, funding, or salary from an organization 
that holds or has applied for patents relating to the content of the manuscript?  
 
5.  Do you have any other financial competing interests?  
 
6.  Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
i declare that i have no com peting interests' below  
 
I agree to the open peer review policy of the journal. I understan d that my name will be included 
on my report to the authors and, if the manuscript is accepted f or publication, my named report 
including any attachments I upload wil l be posted on the website along with the authors' 
responses. I agree for my report to be made available under an Open Access Creative Commons 
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be in cluded as confidential comments 
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal  
Reviewer ’s report  
 
Title: Non-steroidal anti -inflammatory drug -induced enteropathy a s a major risk factor for small 
bowel bleeding: A retrospective study  
 
Version: 1 Date: 21 Apr 2020  
 
Reviewer: Arnaud - Alvès  
 
Reviewer's report:  
 
Please include all comments for the authors in this box rather than uploading your report as an 
attachment. Please only upload as attachments annotated versions of manuscripts, graphs, 
supporting materials or other aspects of your report which cannot be included in a text format.  
Please overwrite this teThe present ma nuscript aimed to assess the frequency of NSAIDs in 
small bowel lesions in Korean patients with obscure GI bleeding who underwent capsule 
endoscopy. This paper is well written and structured. However, there are some comments to 
make in this regard:  
 
1. A recent systematic review and meta -analysis suggested that the optical timing of 
capsule endoscopy would be within 2 days to improve diagnostic yield. Among 
patients with a claer bloody stool, how long did it take to complete the capsule 
endoscopy?  
 
Rebleedin g occurred in 7 patients during the 12 -months follow -up period.  
 
2. Of these seven patients, two had Crohn's disease. What specific treatment did they 
receive for recurrent bleeding?  
 
3. Two patients with radiation enteritis suffered from rebleeding. Surpri singly, they've 
been offered surgical treatment. It's not, however, a classic operative indication for 
radiation enteritis. Did they also have small bowel stenosis on imaging?  
 
4. Finally, multiple strictures of the small bowel were observed on CT -scan in the last 
patient. Were these strictures present prior to the recurrence of bleeding?  
 
The authors suggested the meaningful association between NSAID use and SB injury.  
 
5. Did the authors recommend the use of capsule endoscopy in case of obscure GI 
bleedin g? If that's the case, how soon can this endoscopic capsule be completed?  
 
xt when adding your comments to the authors.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments t o the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Unable to assess  
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain i n your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manus cript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please speci fy what aspects require further 
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing inter ests, considering the following questions:  
 
1.  Have you in the past five years received reimbursements, f ees, funding, or salary 
from an organisation that may in any way gain or lose financial ly from the 
publication of this manuscript, either now or in the future?  
 
2.  Do you hold any stocks or shares in an organisation t hat may in any way gain or 
lose financially from the publication of this manuscript, either now or in the 
future?  
 
3.  Do you hold or are you currently applying for any patents relating to the c ontent 
of the manuscript?  
 
4.  Have you received reimbursements, fees, funding, or salary from an organization 
that holds or has applied for patents relating to the content of the manuscript?  
 
5.  Do you have any other financial competing interests?  
 
6.  Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
i declare that i have no com peting interests' below  
 
I agree to the open peer review policy of the journal. I understan d that my name will be included 
on my report to the authors and, if the manuscript is accepted f or publication, my named report 
including any attachments I upload wil l be posted on the website along with the authors' 
responses. I agree for my report to be made available under an Open Access Creative Commons 
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be in cluded as confidential comments 
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal  
Please review this paper.
user
Reviewer ’s report  
 
Title: Non-steroidal anti -inflammatory drug -induced enteropathy a s a major risk factor for small 
bowel bleeding: A retrospective study  
 
Version: 1 Date: 21 Apr 2020  
 
Reviewer: Arnaud - Alvès  
 
Reviewer's report:  
 
Please include all comments for the authors in this box rather than uploading your report as an 
attachment. Please only upload as attachments annotated versions of manuscripts, graphs, 
supporting materials or other aspects of your report which cannot be included in a text format.  
Please overwrite this teThe present ma nuscript aimed to assess the frequency of NSAIDs in 
small bowel lesions in Korean patients with obscure GI bleeding who underwent capsule 
endoscopy. This paper is well written and structured. However, there are some comments to 
make in this regard:  
 
1. A recent systematic review and meta -analysis suggested that the optical timing of 
capsule endoscopy would be within 2 days to improve diagnostic yield. Among 
patients with a claer bloody stool, how long did it take to complete the capsule 
endoscopy?  
 
Rebleedin g occurred in 7 patients during the 12 -months follow -up period.  
 
2. Of these seven patients, two had Crohn's disease. What specific treatment did they 
receive for recurrent bleeding?  
 
3. Two patients with radiation enteritis suffered from rebleeding. Surpri singly, they've 
been offered surgical treatment. It's not, however, a classic operative indication for 
radiation enteritis. Did they also have small bowel stenosis on imaging?  
 
4. Finally, multiple strictures of the small bowel were observed on CT -scan in the last 
patient. Were these strictures present prior to the recurrence of bleeding?  
 
The authors suggested the meaningful association between NSAID use and SB injury.  
 
5. Did the authors recommend the use of capsule endoscopy in case of obscure GI 
bleedin g? If that's the case, how soon can this endoscopic capsule be completed?  
 
xt when adding your comments to the authors.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments t o the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Unable to assess  
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain i n your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manus cript or would you recommend an 
additional statistical review?  
If an additional statistical review is recommended, please speci fy what aspects require further 
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing inter ests, considering the following questions:  
 
1.  Have you in the past five years received reimbursements, f ees, funding, or salary 
from an organisation that may in any way gain or lose financial ly from the 
publication of this manuscript, either now or in the future?  
 
2.  Do you hold any stocks or shares in an organisation t hat may in any way gain or 
lose financially from the publication of this manuscript, either now or in the 
future?  
 
3.  Do you hold or are you currently applying for any patents relating to the c ontent 
of the manuscript?  
 
4.  Have you received reimbursements, fees, funding, or salary from an organization 
that holds or has applied for patents relating to the content of the manuscript?  
 
5.  Do you have any other financial competing interests?  
 
6.  Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
i declare that i have no com peting interests' below  
 
I agree to the open peer review policy of the journal. I understan d that my name will be included 
on my report to the authors and, if the manuscript is accepted f or publication, my named report 
including any attachments I upload wil l be posted on the website along with the authors' 
responses. I agree for my report to be made available under an Open Access Creative Commons 
CC-BY license ( http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments 
which I do not wish to be included in my named report can be in cluded as confidential comments 
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal  
assistant